公开(公告)号：US20150152154A1

公开(公告)日：2015-06-04

申请号：US14457897

申请日：2014-08-12

Applicant: BioNTech AG

Inventor： Thorsten Klamp ,  Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Thomas Hiller ,  Jens Schumacher

IPC: C07K14/47 ,  A61K39/00 ,  C12N7/00 ,  C07K14/005

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/523 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6075 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N7/00 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10143 ,  C12N2730/10171

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract translation: 本发明涉及使用包含全部或部分乙型肝炎病毒核心抗原蛋白的嵌合蛋白和包含衍生自肿瘤相关抗原的细胞外部分的表位的氨基酸序列的肿瘤免疫治疗，特别是肿瘤免疫接种。 特别地，本发明提供了包含所述嵌合蛋白的病毒样颗粒，其可用于在受试者内针对肿瘤相关抗原，特别是针对在其表面上携带所述肿瘤相关抗原的细胞引起体液免疫应答，其中 肿瘤相关抗原是所述受试者的自身蛋白质。

公开(公告)号：US20170072035A1

公开(公告)日：2017-03-16

申请号：US15341528

申请日：2016-11-02

Applicant: BioNTech AG

Inventor： Thorsten Klamp ,  Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Thomas Hiller ,  Jens Schumacher

IPC: A61K39/00 ,  C07K14/47 ,  C12N7/00 ,  C07K14/005

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract translation: 本发明涉及使用包含全部或部分乙型肝炎病毒核心抗原蛋白的嵌合蛋白和包含衍生自肿瘤相关抗原的细胞外部分的表位的氨基酸序列的肿瘤免疫治疗，特别是肿瘤免疫治疗。 特别地，本发明提供了包含所述嵌合蛋白的病毒样颗粒，其可用于在受试者内针对肿瘤相关抗原，特别是针对在其表面上携带所述肿瘤相关抗原的细胞引起体液免疫应答，其中 肿瘤相关抗原是所述受试者中的自身蛋白质。

公开(公告)号：US09617321B2

公开(公告)日：2017-04-11

申请号：US14457897

申请日：2014-08-12

Applicant: BioNTech AG

Inventor： Thorsten Klamp ,  Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Thomas Hiller ,  Jens Schumacher

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/005 ,  C12N7/00

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/523 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6075 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N7/00 ,  C12N2730/10123 ,  C12N2730/10134 ,  C12N2730/10143 ,  C12N2730/10171

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

公开(公告)号：US20150099302A1

公开(公告)日：2015-04-09

申请号：US14571425

申请日：2014-12-16

Applicant: BioNTech AG ,  Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Torsten Seppmann ,  Holger Hoff ,  Jens Schumacher

IPC: C07K14/705 ,  C12N5/0781 ,  C07K16/00

CPC classification number: C07K14/70578 ,  C07K16/00 ,  C07K2319/30 ,  C12N5/0635

Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.

Abstract translation: 本发明提供重组蛋白，其包含CD40的细胞内节段的氨基酸序列和介导重组蛋白与免疫球蛋白重链的恒定区的缔合的氨基酸序列。 根据本发明的重组蛋白质可用于诱导具有预定抗原特异性的B细胞的克隆扩增，而不需要T细胞或CD40L介导的共刺激。 因此，本发明提供了用于针对感兴趣的抗原特异性的B细胞的克隆扩增的工具，以及产生分泌针对感兴趣的抗原的抗体的B细胞。 本发明的重组蛋白还可用于从人受试者的B细胞库中产生具有预定抗原特异性的完全人单克隆抗体。

公开(公告)号：US10526387B2

公开(公告)日：2020-01-07

申请号：US15341528

申请日：2016-11-02

Applicant: BioNTech AG

Inventor： Thorsten Klamp ,  Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Thomas Hiller ,  Jens Schumacher

IPC: C07K14/47 ,  A61K39/00 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

公开(公告)号：US09139639B2

公开(公告)日：2015-09-22

申请号：US14571425

申请日：2014-12-16

Applicant: BioNTech AG ,  Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Torsten Seppmann ,  Holger Hoff ,  Jens Schumacher

IPC: C12N15/12 ,  C12N15/11 ,  C12N15/63 ,  C07K14/705 ,  C07K16/00 ,  C12N5/0781

CPC classification number: C07K14/70578 ,  C07K16/00 ,  C07K2319/30 ,  C12N5/0635

Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are—useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.

Abstract translation: 本发明提供重组蛋白，其包含CD40的细胞内节段的氨基酸序列和介导重组蛋白与免疫球蛋白重链的恒定区的缔合的氨基酸序列。 根据本发明的重组蛋白质可用于诱导具有预定抗原特异性的B细胞的克隆扩增，而不需要T细胞或CD40L介导的共刺激。 因此，本发明提供了用于针对感兴趣的抗原特异性的B细胞的克隆扩增的工具，以及产生分泌针对感兴趣的抗原的抗体的B细胞。 本发明的重组蛋白还可用于从人受试者的B细胞库中产生具有预定抗原特异性的完全人单克隆抗体。